Regulating Drug Release Behavior and Kinetics from Matrix Tablets Based on Fine Particle-Sized Ethyl Cellulose Ether Derivatives : An In Vitro and In Vivo Evaluation

Abstract EN

The design and fabrication of sustained/controlled release dosage forms, employing new excipients capable of extending/controlling the release of drugs from the dosage forms over prolonged periods, has worked well in achieving optimally enhanced therapeutic levels of the drugs.

In this sense, the objective of this study was to investigate the suitability of selected cellulose ether derivatives for use in direct compression (DC) and as efficient drug release controlling agents.

Controlled release matrix tablets of ciprofloxacin were prepared at different drug-to-polymer (D : P) ratios by direct compression using a fine particle sized ethylcellulose ether derivative (ETHOCEL Standard Premium 7FP) as rate controlling polymer.

The tablets obtained were evaluated for various physico-chemical characteristics and in-vitro drug release studies were conducted in phosphate buffer (pH 7.4) using PharmaTest dissolution apparatus at constant temperature of 37°C±0.1.

Similarity factor f2 was employed to the release profiles of test formulations and were compared with marketed ciprofloxacin conventional tablets.

Drug release mechanism and the kinetics involved were investigated by fitting the release profile data to various kinetic models.

It was found that with increasing the proportion of ethylcellulose ether derivative in the matrix, the drug release was significantly extended up to 24 hours.

The tablets exhibited zero order or nearly zero order drug transport mechanism.

In vivo drug release performance of the developed controlled release tablets and reference conventional tablets containing ciprofloxacin were determined in rabbit serum according to randomized two-way crossover study design using High Performance Liquid Chromatography.

Several bioavailability parameters of both the test tablets and conventional tablets including Cmax, Tmax and AUC0-t were compared which showed an optimized Cmax and Tmax (P<0.05).

A good correlation was obtained between in vitro drug release and in vivo drug absorption with correlation value (R2=0.934).

Relative bioavailability was found to be 93%.

Reproducibility of manufacturing process and accelerated stability of the developed tablets were performed in stability chamber at 40±2°C and 75±5% relative humidity for a period of 6 months and were found to be stable throughout the stability period.